IGBA Still Sees A Path To Change FDA’s Mind On Biologic Suffixes

In the second of three exclusive interviews with IGBA secretary general Suzette Kox and chair Jim Keon, Kox provides the latest update on worldwide issues around biosimilars, particularly naming conventions.